viewAnteris Technologies Ltd

Admedus takes significant step forward in developing unique heart valve device

Admedus is aiming to revolutionise the design and engineering of transcatheter aortic valve replacement (TAVR) devices.

human heart
TAVR eliminates the need for open-heart surgery

Admedus Ltd (ASX:AHZ) has submitted several new provisional patent applications in the US for further development of its novel Transcatheter Aortic Valve Replacement (TAVR) device.

TAVR is where a valve is placed into the heart via a catheter (usually inserted through the leg) to replace the aortic valve, eliminating the need for open-heart surgery.

Admedus’ new TAVR device is designed to reduce the risks associated with the insertion and placement of the valve.

READ: Admedus heart valve device in development passes key milestone

The provisional patents relate to the engineering of key TAVR device components; two of which are designed to improve the fit, as well as valve placement and positioning.

The third component is designed to reduce the incidence of paravalvular leakage (PVL) which can lead to higher morbidity and poor health outcomes for patients.

Shares are up almost 10% to 34.5 cents.

Admedus’ specially engineered delivery system offers greater precision deployment and placement mechanisms which allow the surgeon to achieve a more optimal fit and reduce the risk of PVL.

US$5 billion market by 2020

TAVR is considered the best alternative treatment for patients unable to undergo surgical aortic valve replacement (SAVR).

The demand for TAVR devices is growing rapidly - current market value is estimated at US$3.5 billion and expected to increase to US$5 billion by 2020.

Building on the success of ADAPT® tissue technology

The company had previously submitted patent applications for a unique 3D moulded single-piece valve, using its novel ADAPT tissue technology.

The new components have been designed to complement the single-piece moulded valve, and to address significant unmet needs in the areas of valve placement and positioning.

Admedus chief executive Wayne Paterson said: “This is another significant step forward for Admedus as these patent applications take the company into new territory.

“The benefits of our clinically-superior ADAPT technology and tissue products are now scientifically proven beyond doubt with a decade of clinical data to demonstrate its superior resistance to calcification and toxicity.”

READ: Admedus enters agreement opening sales channel to 1,500 hospitals

Admedus recently entered a purchasing agreement allowing it to promote its flagship ADAPT tissue products, CardioCel® and VascuCel®, to more than 1,500 hospitals in the US.

CardioCel and VascuCel are used to treat heart defects and for heart valve, vessel and cardiovascular repairs.

Quick facts: Anteris Technologies Ltd

Price: 3.99 AUD

Market: ASX
Market Cap: $23.58 m

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Anteris Technologies Ltd named herein, including the promotion by the Company of Anteris Technologies Ltd in any Content on the Site, the...


Admedus CEO in New York to update on recent key milestones

Admedus Ltd (ASX:AHZ) CEO Wayne Paterson visited the Proactive Investors New York studio to update on key milestones the company has achieved in the past few months, including receiving European approval on two of its products.

on 03/17/2019

3 min read